How Does Semaglutide Work? The Mechanism, Explained From the Label

Quick answer

Semaglutide works as a GLP-1 receptor agonist: it binds to and activates the same receptor in the body that the natural gut hormone GLP-1 acts on. As of September 2026, the FDA-approved prescribing information describes four actions that follow from that binding: activation of GLP-1 receptors in brain areas involved in appetite regulation, a decrease in calorie intake, insulin release and glucagon suppression that occur only in a glucose-dependent way, and a delay in gastric emptying.

The rest of this page unpacks those four actions in the words the label uses, adds what peer-reviewed reviews say about the brain, and is honest about the line where mechanism stops explaining anything. There are no doses, no schedules, and no outcome figures here, because none of those belong in an explainer. For the medication class as a whole, start with what a GLP-1 medication is.

What GLP-1 is and where it comes from

GLP-1 stands for glucagon-like peptide-1. It is a hormone your own body makes. Specialized cells in the gut lining, called L-cells and concentrated in the distal ileum and colon, release it into the bloodstream in response to nutrient ingestion. Because it is released by the gut in response to eating and then acts on the pancreas, it belongs to a family of hormones called incretins.

Once in circulation, GLP-1 acts in several places at once. It signals fullness to appetite centers in the brain. It prompts the pancreas to release insulin and to hold back glucagon. It slows the rate at which the stomach passes its contents onward. Together these are the ordinary, everyday signals your body uses to end a meal and handle the sugar that meal delivers.

There is a catch, and it is the reason semaglutide exists as a molecule at all. Native GLP-1 is cleaved by an enzyme called dipeptidyl peptidase-4, usually written DPP-4, which renders it inactive and is responsible for its short half-life. A hormone that short-lived cannot be given as a medication in its natural form, so the useful question is not how to supply more GLP-1 but how to build something that activates the same receptor and survives long enough to matter.

What a GLP-1 receptor agonist does at the receptor

An agonist is a molecule that binds to a receptor and switches it on, the way the body's own signal would. The GLP-1 receptor is a G protein-coupled receptor, a common design in which the receptor sits across the cell membrane, senses a signal outside, and changes shape to start a chain of events inside.

Reviews of GLP-1 receptor signaling describe what happens next: the receptor couples to Gs proteins, which stimulate production of the second messenger cyclic AMP inside the cell. A second messenger does not carry the original message, it carries the cell's response to it. What that response looks like depends entirely on which cell you are standing in. In a pancreatic beta cell, raised cyclic AMP pushes insulin toward release. In a neuron in an appetite circuit, it changes how that neuron fires. In smooth muscle in the stomach wall, the downstream effect is reduced motility.

This is the part worth holding onto, because it explains why one molecule produces effects that sound unrelated. There is not a separate appetite drug and a separate blood sugar drug inside semaglutide. There is one receptor, in many tissues, and the tissue decides what activation means. It is also why appetite is better understood as a signalling system than as a measure of willpower. The receptors described here are part of how the body ends a meal, and they are doing that work whether or not anyone is thinking about it. A 2024 review in Frontiers in Endocrinology describes the incretin side of this plainly, noting that GIP and GLP-1 "play roles in regulating food intake by stimulating neurons in the brain's satiety center."

How does semaglutide work, according to the FDA label?

Section 12.1 of the FDA-approved label is the primary statement of mechanism, written by the manufacturer and cleared by the agency. The label for the approved injection product states:

From the WEGOVY label, section 12.1, Mechanism of Action: "Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological regulator of appetite and caloric intake, and the GLP-1 receptor is present in several areas of the brain involved in appetite regulation."

Three things are worth pulling out of that. First, selectivity: semaglutide is described as binding the GLP-1 receptor specifically, not as a general metabolic stimulant. Second, the label frames GLP-1 itself as a regulator of appetite and calorie intake, so appetite is not a side effect of the mechanism, it is the mechanism. Third, the label locates GLP-1 receptors in brain regions involved in appetite regulation, and it adds that animal studies show semaglutide distributed to and activated neurons in those regions.

The same section is also candid about its own limits. On cardiovascular risk it states that the exact mechanism has not been established, and on liver disease it says the precise mechanism is not fully understood. A label that says "not established" where the evidence is thin is a useful model for how to read everything else it does say.

Semaglutide is nearly identical in sequence to human GLP-1, which is why it fits the same receptor. It is not identical, and the differences are deliberate.

Why semaglutide lasts longer than the GLP-1 your own gut makes

Section 11, the DESCRIPTION section of the label, sets out the engineering in one paragraph. The peptide backbone is made by yeast fermentation, and then three changes are made to it.

The label states: "The main protraction mechanism of semaglutide is albumin binding, facilitated by modification of position 26 lysine with a hydrophilic spacer and a C18 fatty di-acid." Protraction simply means making the effect last. Albumin is the most abundant protein in blood plasma, and a molecule that rides along attached to it is shielded from being filtered out by the kidneys and from being broken down.

The second change addresses the enzyme problem directly. Again from the label: semaglutide "is modified in position 8 to provide stabilization against degradation by the enzyme dipeptidyl-peptidase 4 (DPP-4)." That is the modification that answers the reason native GLP-1 cannot be a drug. The third is housekeeping: a minor modification at position 34 ensures only one fatty di-acid attaches, so every molecule made is the same molecule.

The type 2 diabetes tablet label states the combined result: albumin binding is "the principal mechanism of protraction resulting in the long half-life of semaglutide," producing decreased renal clearance and protection from metabolic degradation. Half-life is a concept worth knowing: it is the time it takes for the amount of a drug in the blood to fall by half. A short half-life means a substance clears quickly, a long one means it lingers and its level changes slowly. This page gives no figure for it, because half-life numbers lead directly to dosing arithmetic, and dosing is a prescriber's decision, not a reader's.

Delayed gastric emptying, in the label's words

Section 12.2, pharmacodynamics, is where the label describes what the drug does to the body. For the injection product the sentence is as short as sentences get: "Semaglutide delays gastric emptying."

Gastric emptying is the rate at which the stomach passes food into the small intestine. Slow it down and the stomach stays occupied longer after a meal, which is felt as fullness that persists rather than fading in an hour. It also means the sugar from that meal arrives in the bloodstream more gradually.

The RYBELSUS and OZEMPIC tablets label describes something narrower. It states that semaglutide "causes a delay of early postprandial gastric emptying, thereby reducing the rate at which glucose appears in the circulation postprandially," and elsewhere calls this a minor delay in the early postprandial phase. Postprandial means after eating. The difference in wording between the two labels is not decoration: it reflects different products, different routes, and different evidence packages, and it is a reminder that "semaglutide" is not one uniform experience.

This same mechanism is the honest explanation for the gastrointestinal complaints people report. A stomach that empties more slowly can feel full, and it can also feel nauseated, bloated, or uncomfortable. The cause of the wanted effect and the cause of the unwanted one are the same physiology. This page does not list side effects or their frequencies. That belongs in a dedicated piece: see the semaglutide side effects guide.

Insulin, glucagon, and why glucose dependence matters

The label states that semaglutide "stimulates insulin secretion and reduces glucagon secretion in a glucose-dependent manner," and that these effects can lead to a reduction of blood glucose.

Glucagon is insulin's counterpart. Where insulin moves glucose out of the blood, glucagon tells the liver to put glucose into it. Lowering glucagon while raising insulin pushes blood sugar in one direction.

The phrase doing the real work in that sentence is "glucose-dependent." It means the effect is conditional on blood sugar being high. When glucose is elevated, insulin secretion is stimulated and glucagon secretion is inhibited. When glucose is not elevated, the mechanism is not pushing insulin out regardless. The RYBELSUS and OZEMPIC tablets label adds a specific observation, and it names the population that observation came from: during induced hypoglycemia, semaglutide did not alter the counter regulatory responses of increased glucagon compared to placebo in patients with type 2 diabetes mellitus. In plain terms, in that population the body's emergency response to low blood sugar was still available. The labels do not attribute low blood sugar to this mechanism acting on its own, and they state plainly where the documented risk does come from: concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. That is a reason for whoever prescribes to know every other medication a person takes.

What the label says about how the body handles semaglutide

Section 12.3 covers pharmacokinetics, which is what the body does to the drug rather than the reverse. Stated without numbers, it reads like this.

Semaglutide is absorbed after administration, and how completely it is absorbed depends heavily on the route: the injection label reports high absolute bioavailability, while the tablets label reports a very low one, which is the whole reason an oral product needs an absorption enhancer built into it. Once absorbed, it is extensively bound to plasma albumin, which the label says results in decreased renal clearance and protection from degradation. It is eliminated mainly by being broken apart, and the resulting material leaves through urine and feces.

The practical consequence, stated qualitatively, is that semaglutide leaves the body slowly. It is present in circulation for weeks after the last dose rather than hours or days. That is a direct result of the albumin binding described above. Anyone who needs that answer for a real decision, such as planning a pregnancy, a procedure, or a medication change, should get it from their own prescriber rather than from any article.

Why the oral tablet needs an absorption enhancer

Semaglutide is a peptide, which is to say a small protein. Swallowing a protein normally means digesting it. Stomach acid and digestive enzymes exist precisely to take proteins apart into fragments, and a peptide drug that went through that process intact would be the exception, not the rule.

The RYBELSUS and OZEMPIC tablets label states the workaround directly: the tablets "are co-formulated with SNAC which facilitates the absorption of semaglutide after oral administration. The absorption of semaglutide predominantly occurs in the stomach."

SNAC is salcaprozate sodium, and the label lists it as an inactive ingredient in the tablet formulations. Its job is to make absorption across the stomach lining possible at the local site where the tablet dissolves. This is why an oral GLP-1 tablet is not simply the injection in pill form: it is a different formulation problem with a different solution built into it, and the label's own absorption data show the route changes how much drug gets in. For how the oral and injectable forms compare as options, see oral and sublingual GLP-1 forms.

Appetite, reward, and what people call food noise

This is the most interesting part of the mechanism and also the part where the evidence needs the most careful handling, so the sourcing is named as it goes.

The label establishes the starting point: GLP-1 receptors are present in several brain areas involved in appetite regulation, and animal studies show semaglutide distributed to and activated neurons in brain regions involved in regulation of food intake.

The most-cited study behind that sentence is Gabery and colleagues, published in JCI Insight in 2020, and it is a rodent study. Its finding is specific: "Semaglutide directly accessed the brainstem, septal nucleus, and hypothalamus but did not cross the blood-brain barrier; it interacted with the brain through the circumventricular organs and several select sites adjacent to the ventricles." Circumventricular organs are small regions where the usual barrier between blood and brain is deliberately leaky, which is how the brain samples what is circulating. The same paper reported that semaglutide modulated food preference in those animals, not only how much they ate, which is the thread that connects this mechanism to the brain's reward pathways rather than to hunger alone. That connection is still preclinical: it was measured in rodents, and it has not been confirmed in humans.

Patients often describe something the research literature has only recently tried to define, the constant background hum of thinking about food. A 2025 paper in Nutrition and Diabetes proposes a formal definition: food noise is "persistent thoughts about food that are perceived by the individual as being unwanted and/or dysphoric and may cause harm to the individual." That paper is a definitional and measurement paper. It describes developing a questionnaire and lists the effect of GLP-1 receptor agonists on food noise as a direction for future research, not as a settled finding. Treating a mechanism that is plausible and under study as though it were established is exactly the error worth avoiding here.

A 2024 review in Current Issues in Molecular Biology puts the caution in the strongest form, noting that "most of the supporting evidence on the mechanistic actions of semaglutide is preclinical, demonstrated in rodents and not actually confirmed in humans, therefore warranting caution in the interpretation."

What the mechanism does not tell you about any one person

Mechanism describes what a molecule does at a receptor. It does not describe what will happen to you.

A mechanism cannot tell you whether a medication is appropriate for you, because that depends on your health history, your other medications, and conditions that may rule it out entirely. It cannot tell you how your body will respond, because response varies between people for reasons that are still being worked out. It cannot tell you whether you will tolerate it, because tolerability varies too. And it cannot tell you anything about magnitude or timing, which is why this page deliberately carries no figures and no timelines.

There is one more limit worth stating plainly, because it is the one most often blurred. Every label section quoted on this page describes an FDA-approved product. Compounded medications are not FDA-approved as final products. The label evidence above is evidence about the approved products it belongs to, and it should not be read as evidence about any other preparation.

Whether any prescription medication is appropriate at all is a decision for a licensed physician who has reviewed your history, not something an explainer can settle.

What semaglutide is approved to treat, by label

Approved uses are set by the label, and they differ by product, which is why "semaglutide is approved for weight loss" is too loose to be accurate. Semaglutide is the active ingredient in more than one FDA-approved product, and their labels are not interchangeable. The injection label quoted throughout this page is Wegovy's, and that same Wegovy label also covers Wegovy tablets. A separate label covers Rybelsus and Ozempic tablets. Where the labels say different things, the difference is the product, not the molecule.

The approved injection product is indicated, in combination with a reduced calorie diet and increased physical activity, to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, and to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition. That label also carries an indication, granted under accelerated approval, for noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis in adults.

Oral semaglutide tablets do not all share one indication, which is why the route tells you nothing on its own. The RYBELSUS and OZEMPIC tablets label, effective January 30, 2026, indicates those tablets as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who are at high risk for those events. The WEGOVY label, effective June 18, 2026, covers both an injection and a tablet, and it indicates WEGOVY tablets, in combination with a reduced calorie diet and increased physical activity, to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, and to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition. The specific product's label decides the indication, not whether the product is swallowed or injected.

Two details deserve emphasis. The weight-related indications are written "in combination with a reduced calorie diet and increased physical activity," so diet and activity are part of the approved use rather than an optional add-on. And the label states a limitation of use: taking a semaglutide product together with another semaglutide-containing product or any other GLP-1 receptor agonist is not recommended.

For questions about coverage, access, or what to ask a clinician, see help.

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider. Compounded medications are not FDA-approved as final products. Medication is prescribed only if a licensed physician determines it is appropriate.

Telehealth prescribing rules differ by state. Read the state-by-state guide.